HMGCR and breast carcinoma: Preoperative statin use was not significantly associated with the breast cancer-free interval, overall (Log-Rank P = 0.58) or in any of the tumor-specific HMGCR expression subgroups; no staining (Log-Rank P = 0.32), weak (Log-Rank P = 0.055) or moderate/strong expression (Log-Rank P = 0.79).